Cisplatin / eff Cancer Research Results

Cisplatin, Cisplatin: Click to Expand ⟱
Features:
Cisplatin is a chemotherapy medication used to treat various types of cancer. It is a platinum-based drug that works by interfering with the DNA of cancer cells, preventing them from reproducing and ultimately leading to cell death.
Cisplatin (cis-diamminedichloroplatinum II; CDDP) is a platinum-based chemotherapeutic agent that forms covalent DNA crosslinks, primarily intrastrand adducts at adjacent guanine bases. These distort DNA structure, block replication and transcription, and activate DNA damage response pathways (ATM/ATR → p53), leading to cell-cycle arrest and apoptosis. Secondary mechanisms include ROS generation, stress MAPK activation, and modulation of NF-κB. Clinical resistance frequently involves enhanced DNA repair (ERCC1/NER), altered drug transport (CTR1, ATP7A/B), and increased antioxidant defenses. Major toxicities include nephrotoxicity, ototoxicity, and peripheral neuropathy.

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 DNA crosslink formation (intrastrand adducts) DNA adducts ↑; replication block ↑ Normal dividing cells also affected P, R, G Direct DNA cytotoxicity Cisplatin forms covalent intrastrand crosslinks (primarily at adjacent guanines), distorting DNA and blocking replication and transcription.
2 DNA damage response (ATM / ATR → p53) Checkpoint activation ↑; p53 signaling ↑ ↔ (toxicity in proliferating tissues) R, G Damage signaling cascade DNA distortion activates ATM/ATR pathways leading to p53-mediated cell-cycle arrest and apoptosis.
3 Intrinsic apoptosis (mitochondrial pathway) Bax ↑; Bcl-2 ↓; caspase-9/3 ↑ Nephrotoxicity & ototoxicity risk G Execution of cell death Persistent DNA damage triggers mitochondrial outer membrane permeabilization and caspase activation.
4 Cell-cycle arrest (G2/M emphasis) G2/M arrest ↑ G Cytostasis → apoptosis Cells accumulate in G2/M phase due to unrepaired DNA lesions.
5 ROS generation / oxidative stress ROS ↑ (secondary mechanism) Oxidative injury ↑ (kidney, cochlea) R, G Stress amplification Cisplatin increases mitochondrial ROS and oxidative stress, contributing to cytotoxicity and organ toxicity.
6 MAPK signaling (JNK / p38 activation) Stress MAPK activation ↑ R, G Stress-response signaling JNK and p38 activation contribute to apoptosis and stress signaling.
7 NF-κB activation (resistance axis) NF-κB ↑ may promote survival R, G Resistance modulation NF-κB activation can reduce sensitivity; inhibition enhances cytotoxicity in some models.
8 DNA repair pathways (NER / ERCC1) NER ↑ → resistance G Resistance determinant Nucleotide excision repair (ERCC1) removes platinum adducts; high ERCC1 correlates with resistance.
9 Drug transport (CTR1 uptake; ATP7A/B efflux) CTR1 ↓ or ATP7A/B ↑ → resistance G Exposure constraint Copper transporters influence intracellular cisplatin accumulation and resistance.
10 Clinical toxicity profile Nephrotoxicity, ototoxicity, neurotoxicity Translation constraint Major dose-limiting toxicities arise from DNA damage and oxidative stress in normal tissues.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (DNA aquation and initial adduct formation)
  • R: 30 min–3 hr (checkpoint activation / stress signaling)
  • G: >3 hr (apoptosis, phenotype outcomes, resistance development)


eff, efficacy: Click to Expand ⟱
Source:
Type:
Power to enhance an anti cancer effect


Scientific Papers found: Click to Expand⟱
5426- ASTX,  Cisplatin,    Astaxanthin Prevents a Decrease of Hemopoietic Activity in Head and Neck Cancer Patients Receiving Cisplatin Chemotherapy (Randomized Controlled Trial)
- Trial, HNSCC, NA
ROS↓, SOD↑, MDA↓, eff↑,
5862- carbop,  Cisplatin,    Molecular Mechanisms of Resistance and Toxicity Associated with Platinating Agents
- Review, Var, NA
DNAdam↑, ER Stress↑, UPR↑, ATF4↑, ATF6↑, XBP-1↑, GRP78/BiP↑, NP/CIPN↝, toxicity↝, eff↑, TrxR1⇅,
1966- GamB,  Cisplatin,    Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
- in-vitro, Lung, A549 - in-vitro, Lung, NCIH1299
TumCCA↑, PARP↑, eff↑, ROS↑, ChemoSen↑,
2043- PB,  Cisplatin,    Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
- in-vitro, HNSCC, UM-SCC-1
ChemoSen↑, eff↑, HDAC↓, BRCA1↓, RadioS↑,
4965- PSO,  Cisplatin,    The synergistic antitumor effects of psoralidin and cisplatin in gastric cancer by inducing ACSL4-mediated ferroptosis
- vitro+vivo, GC, HGC27 - vitro+vivo, GC, MKN45
TumCP↓, TumCMig↓, TumCI↓, TumCG↓, *toxicity↓, eff↑, Ferroptosis↑, ACSL4↑, GPx4↓, ChemoSen↑, chemoP↑, AntiTum↑, Sepsis↓,
5041- SAS,  Cisplatin,    Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism
- in-vitro, CRC, NA
xCT↓, Inflam↓, Apoptosis↓, GSH↓, ROS↑, TumCG↓, selectivity↑, eff↑, eff↓,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 1,   MDA↓, 1,   ROS↓, 1,   ROS↑, 2,   SOD↑, 1,   TrxR1⇅, 1,   xCT↓, 1,  

Core Metabolism/Glycolysis

ACSL4↑, 1,  

Cell Death

Apoptosis↓, 1,   Ferroptosis↑, 1,  

Protein Folding & ER Stress

ATF6↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

DNA Damage & Repair

BRCA1↓, 1,   DNAdam↑, 1,   PARP↑, 1,  

Cell Cycle & Senescence

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

HDAC↓, 1,   TumCG↓, 2,  

Migration

TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature

ATF4↑, 1,  

Immune & Inflammatory Signaling

Inflam↓, 1,  

Drug Metabolism & Resistance

ChemoSen↑, 3,   eff↓, 1,   eff↑, 6,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers

BRCA1↓, 1,  

Functional Outcomes

AntiTum↑, 1,   chemoP↑, 1,   NP/CIPN↝, 1,   toxicity↝, 1,  

Infection & Microbiome

Sepsis↓, 1,  
Total Targets: 39

Pathway results for Effect on Normal Cells:


Functional Outcomes

toxicity↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: eff, efficacy
6 Cisplatin
1 Astaxanthin
1 carboplatin
1 Gambogic Acid
1 Phenylbutyrate
1 Psoralidin
1 Sulfasalazine
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:197  Target#:961  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page